Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients With Enteric Hyperoxaluria
Conditions
Interventions
SYNB8802
Placebo
Locations
4
United States
Urological Associates of Southern Arizona (open to remote participation)
Tucson, Arizona, United States
Genesis Clinical Research
Tampa, Florida, United States
Knoxville Kidney Center
Knoxville, Tennessee, United States
PRA Health Sciences
Salt Lake City, Utah, United States
Start Date
November 4, 2020
Primary Completion Date
January 17, 2023
Completion Date
January 17, 2023
Last Updated
March 8, 2024
NCT06716502
NCT07310264
NCT00090662
NCT06290258
NCT07483606
NCT06342713
Lead Sponsor
Synlogic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions